Current Prediction-Based Three-Vector Voltage Optimization System for the Induction Motor with Current Static Error Correction

In the present study, the current control method of the model predictive control is applied to the field-oriented control induction motor. The augmentation model of the motor is initially established based on the stator current equation, which performs the current predictive control and formulates the new cost function by means of tracking error. Then, the influence of parameter error on the current control stability in the prediction model is analysed, and the current static error is corrected according to the correlation between the input and feedback. Finally, a simple and effective three-vector control strategy is proposed. Moreover, three adjacent basic voltage vectors are utilized, and then six candidate voltage vectors are synthesized in each sector to replace eight basic voltage vectors in the conventional model predictive control (MPC). The obtained results show that synthesized vectors, which have arbitrary amplitude and direction, significantly expand the coverage of the system’s control set, reduce the torque and flux pulsation in the conventional MPC, and improve the steady-state performance of the system. Finally, the dSPACE platform is employed to validate the performed experiment. It is concluded that the proposed method can reduce the torque and flux pulse, perform the induction motor current control, and improve the steady-state performance of the system

Three Vectors Model Predictive Torque Control Without Weighting Factor Based on Electromagnetic Torque Feedback Compensation

Finite control set-model predictive torque control (FCS-MPTC) depends on the system parameters and the weight coefficients setting. At the same time, since the actual load disturbance is unavoidable, the model parameters are not matched, and there is a torque tracking error. In traditional FCS-MPTC, the outer loop—that is, the speed loop—adopts a classic Proportional Integral (PI) controller, abbreviated as PI-MPTC. The pole placement of the PI controller is usually designed by a plunge-and-test, and it is difficult to achieve optimal dynamic performance and optimal suppression of concentrated disturbances at the same time. Aiming at squirrel cage induction motors, this paper first proposes an outer-loop F-ETFC-MPTC control strategy based on a feed-forward factor for electromagnetic torque feedback compensation (F-ETFC). The electromagnetic torque was imported to the input of the current regulator, which is used as the control input signal of feedback compensation of the speed loop; therefore, the capacity of an anti-load-torque-disturbance of the speed loop was improved. The given speed is quantified by a feed-forward factor into the input of the current regulator, which is used as the feed-forward adjustment control input of the speed controller to improve the dynamic response of the speed loop. The range of the feed-forward factor and feed-back compensation coefficient can be obtained according to the structural analysis of the system, which simplifies the process of parameter design adjustment. At the same time, the multi-objective optimization based on the sorting method replaces the single cost function in traditional control, so that the selection of the voltage vector works without the weight coefficient and can solve complicated calculation problems in traditional control. Finally, according to the relationship between the voltage vector and the switch state, the virtual six groups of three vector voltages can be adjusted in both the direction and amplitude, thereby effectively improving the control performance and reducing the flow rate and torque ripple. The experiment is based on the dSPACE platform, and experimental results verify the feasibility of the proposed F-ETFC-MPTC. Compared with traditional PI-MPTC, the feed-forward factor can effectively improve the stability time of the system by more than 10 percent, electromagnetic torque feedback compensation can improve the anti-load torque disturbance ability of the system by more than 60 percent, and the three-vector voltage method can effectively reduce the disturbance

Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges.

Early observations that cultured mesenchymal stem cells (MSCs) could be induced to exhibit certain characteristics of osteocytes and chondrocytes led to the proposal that they could be transplanted for tissue repair through cellular differentiation. Therefore, many subsequent preclinical studies with transplanted MSCs have strived to demonstrate that cellular differentiation was the underlying mechanism for the therapeutic effect. These studies generally followed the minimal criteria set by The International Society for Cellular Therapy in assuring MSC identity by using CD70, CD90, and CD105 as positive markers and CD34 as a negative marker. However, the three positive markers are co-expressed in a wide variety of cells, and therefore, even when used in combination, they are certainly incapable of identifying MSCs in vivo. Another frequently used MSC marker, Stro-1, has been shown to be an endothelial antigen and whether it can identify MSCs in vivo remains unknown. On the other hand, the proposed negative marker CD34 has increasingly been shown to be expressed in native MSCs, such as in the adipose tissue. It has also helped establish that MSCs are likely vascular stem cells (VSCs) that reside in the capillaries and in the adventitia of larger blood vessels. These cells do not express CD31, CD104b, or α-SMA, and therefore are designated as CD34+CD31-CD140b-SMA-. Many preclinical MSC transplantation studies have also attempted to demonstrate cellular differentiation by using labeled MSCs. However, all commonly used labels have shortcomings that often complicate data interpretation. The β-gal (LacZ) gene as a label is problematic because many mammalian tissues have endogenous β-gal activities. The GFP gene is similarly problematic because many mammalian tissues are endogenously fluorescent. The cell membrane label DiI can be adsorbed by host cells, and nuclear stains Hoechst dyes and DAPI can be transferred to host cells. Thymidine analog BrdU is associated with loss of cellular protein antigenicity due to harsh histological conditions. Newer thymidine analog EdU is easier to detect by chemical reaction to azide-conjugated Alexa fluors, but certain bone marrow cells are reactive to these fluors in the absence of EdU. These caveats need to be taken into consideration when designing or interpreting MSC transplantation experiments

Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges

Early observations that cultured mesenchymal stem cells (MSCs) could be induced to exhibit certain characteristics of osteocytes and chondrocytes led to the proposal that they could be transplanted for tissue repair through cellular differentiation. Therefore, many subsequent preclinical studies with transplanted MSCs have strived to demonstrate that cellular differentiation was the underlying mechanism for the therapeutic effect. These studies generally followed the minimal criteria set by The International Society for Cellular Therapy in assuring MSC identity by using CD70, CD90, and CD105 as positive markers and CD34 as a negative marker. However, the three positive markers are co-expressed in a wide variety of cells, and therefore, even when used in combination, they are certainly incapable of identifying MSCs in vivo. Another frequently used MSC marker, Stro-1, has been shown to be an endothelial antigen and whether it can identify MSCs in vivo remains unknown. On the other hand, the proposed negative marker CD34 has increasingly been shown to be expressed in native MSCs, such as in the adipose tissue. It has also helped establish that MSCs are likely vascular stem cells (VSCs) that reside in the capillaries and in the adventitia of larger blood vessels. These cells do not express CD31, CD104b, or α-SMA, and therefore are designated as CD34+CD31-CD140b-SMA-. Many preclinical MSC transplantation studies have also attempted to demonstrate cellular differentiation by using labeled MSCs. However, all commonly used labels have shortcomings that often complicate data interpretation. The ß-gal (LacZ) gene as a label is problematic because many mammalian tissues have endogenous ß-gal activities. The GFP gene is similarly problematic because many mammalian tissues are endogenously fluorescent. The cell membrane label DiI can be adsorbed by host cells, and nuclear stains Hoechst dyes and DAPI can be transferred to host cells. Thymidine analog BrdU is associated with loss of cellular protein antigenicity due to harsh histological conditions. Newer thymidine analog EdU is easier to detect by chemical reaction to azide-conjugated Alexa fluors, but certain bone marrow cells are reactive to these fluors in the absence of EdU. These caveats need to be taken into consideration when designing or interpreting MSC transplantation experiments

Effect of modified compound calcium phosphate cement on the differentiation and osteogenesis of bone mesenchymal stem cells

Abstract Background The aim of this study is to evaluate the effect of self-invented compound calcium phosphate cement upon the proliferation and osteogenesis of bone mesenchymal stem cells (BMSCs). Methods Four groups including traditional calcium phosphate cement, modified calcium phosphate cement, modified calcium phosphate cement plus bone morphogenetic protein (BMP), and control groups were established. The cell proliferation curve was delineated by MTT. The activity of BMSCs to synthesize alkaline phosphatase (AKP) was evaluated. The growth and invasion of BMSCs were observed. The expression levels of aggrecan, collagen I, collagen II, AKP, and OSX messenger RNA (mRNA) were measured by using RT-PCR. Results Compared with other groups, the BMSCs in the modified calcium phosphate cement group presented with loose microstructure and the BMSCs closely attached to the vector margin. At 7 days after co-culture, the expression of AKP in the modified calcium phosphate cement plus BMP group was significantly upregulated compared with those in other groups. In the modified calcium phosphate cement group, the BMSCs properly proliferated on the surface of bone cement and invaded into the cement space. At 10 days, the expression levels of aggrecan, collagen I, collagen II, AKP, and OSX mRNA in the modified calcium phosphate cement and modified calcium phosphate cement plus BMP groups were significantly upregulated than those in other groups. Conclusions Modified compound calcium phosphate cement possesses excellent biocompatibility and osteogenic induction ability. Loose microstructure and large pore size create a favorable environment for BMSCs proliferation and vascular invasion, as an ideal vector for releasing BMP cytokines to mediate the differentiation and osteogenesis of BMSCs